Filing Flows › Industrials › Cytek Biosciences (CTKB)
Cytek Biosciences (CTKB) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Cytek Biosciences (CTKB) Q3 2026 earnings results →
Q3 2026 Revenue up 2% year over year to $53.2M · 11¢ of every $1 of revenue lost · operating margin -15.8%
Cytek Biosciences made $53.2M in Q3 2026 (+2% Y/Y): Product $37.2M, Service $16.1M. Operating margin -15.8%, net loss $6.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $53.2M in Q3 2026, up 2% year over year and up 11% from the previous quarter. Product was the largest line at 70% of revenue. Service added $1.9M year over year (up 13%), 202% of the total change. Product declined 3%.
Gross margin was 58.6%, up 5.9 points from Q3 2025. Operating costs exceeded revenue by $8.4M, an operating margin of -15.8%. Operating expenses grew 8% against revenue growth of 2%. The fastest-growing cost line was General & admin (+14%). The quarter ended with a net loss of $6.1M, narrower than the previous quarter's $12.2M loss. Non-operating items added $1.5M, -22% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$4.5M. Non-cash charges added back $2.1M of depreciation and amortization and $4.9M of share-based compensation. Working capital and other items used $5.3M. Capital expenditures of $1.5M exceeded it, leaving free cash flow of −$6.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $53.2M | +2% | -15.8% | −$6.1M | −$4.5M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $48.1M | +6% | -23.7% | −$12.2M | $1.4M |
| Q1 2026 | 10-Q | May 7, 2026 | $44.1M | +6% | -41.8% | −$18.9M | −$2.7M |
| Q4 2025 | 10-K | Feb 26, 2026 | $62.1M | +8% | -9.0% | −$44.1M | −$771K |
| Q3 2025 | 10-Q | Nov 5, 2025 | $52.3M | +2% | -17.6% | −$5.5M | −$3.9M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $45.6M | -2% | -23.3% | −$5.6M | $108K |
| Q1 2025 | 10-Q | May 8, 2025 | $41.5M | -8% | -36.1% | −$11.4M | −$125K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Cytek Biosciences
We are a leading cell analysis solutions company advancing the next generation of research and clinical tools with our novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full Spectrum Profiling” or “FSP” technology). Our goal is to become the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications. Biological systems are highly complex, and scientists are challenged by the multitude of questions that remain unanswered. Analysis at the single-cell level is essential to understand these complex systems. Identifying the correct cell in the context of a given biological question can have profound implications for drug development and health care decisions.
In its own words, from its 10-K, filed Feb 26, 2026.
Cytek Biosciences against its Laboratory Analytical Instruments peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +2% against the peers' median +4%. Operating margin: -15.8% against the peers' median 8.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CTKB Cytek Biosciences | Q3 2026 | $53.2M | +2% | -15.8% |
| A Agilent Technologies | Q3 FY26 | $1.9B | +8% | 23.6% |
| WAT Waters | Q3 2026 | $1.8B | +121% | 7.2% |
| AVTR Avantor | Q3 2026 | $1.7B | +5% | 8.2% |
| ILMN Illumina | Q3 2026 | $1.1B | +4% | 27.0% |
| MTD Mettler Toledo International | Q3 2026 | $1.1B | +6% | 27.4% |
| BRKR Bruker | Q3 2026 | $874M | +2% | -10.4% |
| RVTY Revvity | Q3 2026 | $729M | +4% | 10.6% |
| BIO Bio-Rad Laboratories | Q3 2026 | $656M | +0.5% | -7.6% |
Source: Cytek Biosciences 10-Q on SEC EDGAR · CIK 1831915 · Laboratory Analytical Instruments
Guidance and outlook
13F: who owns CTKB and who is buying
More on CTKB
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results